Field notes and portfolio ideas.

All perspectives

Posts, papers, podcasts & talks.

The thinking that informs the portfolio. Filterable by format and by theme, newest first.

Podcast 6 Oct 2026
Far From The Finishing Post – Agents Inside the Capital Cycle
Django Davidson joins Tom Yeowart on the Far From The Finishing Post podcast. They discuss the nuances of capital cycle…
LISTEN →
Hosking Post 10 Sep 2026
‘Death of the Brand’ or dearth of thought?
Some ten years ago, in the cavernous QEII Conference Centre in front of a 600-person audience, a precocious 37-year-old version…
Read →
Active Ownership Report 24 Aug 2026
Q2 2026 – ESG and Active Ownership Report
After another dynamic quarter, dominated by trillion-dollar IPOs and ongoing geopolitical turmoil, we take a different approach in our Active…
Read →
Podcast 10 Aug 2026
Merryn Talks Money – The Capital Cycle Is Turning
Luke Bridgeman, joins Merryn Somerset Webb for a wide-ranging exploration of our portfolio including discussions on Japan, energy markets, and…
LISTEN →
Quarterly Report 21 Jul 2026
Q2 2026 – Quarterly Report Commentary
The Hosking Partners strategy delivered another strong period of absolute returns, adding 11.7% (net) in the second quarter and taking…
Read →
Podcast 21 Jul 2026
Value Investing with Legends Podcast
The Capital Cycle: Finding Opportunity Where Others Aren't Looking
LISTEN →
Hosking Post 16 Jul 2026
Fit for Purpose
“Aw, baby, how you doing? You know I’m gonna cut right to the chase, huh? Some women were made But…
Read →
Hosking Post 2 Jul 2026
‘Normal’ Service Resumes
Michael Godfrey on the end of the zero-rate anomaly - and the comeback of capital cycle investing.
Read →
Hosking Post 9 Jun 2026
Super cycle or capital cycle?
Luke Bridgeman on our long-term DRAM position.
Insights →
Hosking Post 3 Jun 2026
Paint by numbers
An update on M&A activity across the portfolio.
Read →
Event 26 May 2026
Ed Conway on ‘The Material World’ – Spring Drinks 2026
The highlights from Django Davidson in conversation with Ed Conway.
Read →
Hosking Post 20 May 2026
Syncona
In the crosshairs of Big Pharma.
Read →
Showing 12 of 115 entries Load more →
Mailing list